Imaging Biomarkers Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019
Albany, New York (PRWEB) June 19, 2014
Biomarkers also known as biological markers are characteristics that are measured in order to assess and predict biological condition of the body and thus help physicians in clinical decision making. Some major diseases which are diagnosed by using biomarkers include diabetes, cancer and cardiovascular and central nervous system diseases. Biomarkers play critical role in identifying and accurate diagnosis of these diseases at early stage and provide better treatment option. Imaging biomarkers can be classified as diagnostic biomarkers, monitoring biomarkers and predictive biomarkers. Diagnostic biomarkers are helpful in predicting a patient’s exact clinical outcome. Monitoring biomarkers provides clinical outcome of a patient after intake of a particular drug while predictive biomarkers help in predicting if a specific drug is likely to change clinical outcome of a patient.
More information about Imaging Biomarkers Market: http://www.transparencymarketresearch.com/imaging-biomarkers-market.html.
Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, Affymetrix Inc., Danaher Corporation, Bio-Rad Laboratories Inc., F. Hoffmann La Roche Ltd., Gen-Probe Inc., DiagnoCure Inc., and Siemens Healthcare are some major companies operating in the imaging biomarkers market and compete with each other in order to get competitive advantage. Small companies with breakthrough technologies attract large players to form alliances and thus help them gain advantages over their competitors.
Globally, the market for imaging biomarkers is evolving due to its increasing popularity and extensive use in drug discovery processes. The industry has witnessed a significant use of imaging biomarkers in the drug discovery process during the last few years owing to its ability to identifying disease mechanism and drug toxicity profiling. High prevalence of diseases such as cancer, Alzheimer’s disease, diabetes, rheumatoid arthritis and other slow progressing diseases are driving the imaging biomarkers market growth globally. According to Surveillance, Epidemiology, and End Results Program of National Cancer Institute, approximately 13,397,159 people were living with all cancer types in the United States in 2011. The study conducted by of National Cancer Institute further states that during 2014, around 1,666,540 new cases of cancer are expected to be witnessed in the United States and approximately 585,720 deaths because of all cancer sites. Statistics from American Diabetes Association suggests that approximately 26 million children and adults are living with diabetes in the United States. American Diabetes Association further states that nearly 1.9 people are diagnosed with diabetes every year in the country. On the basis of high prevalence and incidence rate associated with the above mentioned diseases, it can be concluded that rising prevalence of these diseases are likely to drive the market growth during the coming years. However, the market may face significant challenges due to significant variance in platforms available across multiple sites and Lack of standard data. High cost associated with the development of imaging biomarkers may also hamper the market growth to some extent.
For further inquiries, click here: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2381.
Geographically, North America is the largest market for imaging biomarkers, followed by Europe, Asia-Pacific and Rest of the World (RoW). Well established healthcare infrastructure in the region is one of the key factors causing North America to lead the imaging biomarkers market globally. In Asia-Pacific region, the market is expected to grow under the influence of factors such as emerging economies (especially in India and China), continuously improving healthcare infrastructure and rising awareness regarding the imaging biomarkers and its application in drug discovery processes. Presence of large pool of patients living with various slow progressing diseases such as cancer and diabetes is also driving the market growth in the region.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include:
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
90 Sate Street, Suite 700
Albany, NY 12207
USA/Canada Toll Free: 866-552-3453